CXCL8 and melanoma: Furthermore, the activation of β-adrenergic in melanoma, colon cancer, ovarian cancer and multiple myeloma has also been shown to lead to the release of IL-6 or IL-8, in addition to VEGF, contributing to the angiogenic response (262).